Τίτλος:
Prognostic impact of indoleamine 2,3-dioxygenase 1 (IDO1) mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background We sought to determine the prognostic role of indoleamine 2,3-dioxygenase 1 (IDO1) by evaluating IDO1 expression in circulating tumour cells (CTCs) at baseline and after completion of chemoradiotherapy in patients with locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) treated with curative intent. Methods In a prospective cohort of 113 patients with LA HNSCC, we evaluated expression of IDO1 in the EpCAM+ CTC fraction at baseline and after cisplatin chemoradiation. The prognostic value of combined programmed cell death ligand-1 (PDL-1) and IDO1 expression was assessed. Results IDO1 was significantly overexpressed at baseline compared with the post-treatment counterparts (p=0.007). IDO1 messenger RNA (mRNA) expression at baseline was associated with better survival in terms of progression-free survival (PFS) (HR=0.19, p=0.017). Post-treatment IDO1 mRNA levels were correlated with unfavourable prognosis in terms of overall survival (OS) (HR=3.27, p=0.008). Patients with combined decreased expression levels of PDL-1 and IDO1 after treatment exhibited superior PFS (p=0.043) and OS (p=0.021). Conclusions Our results strongly suggest that IDO1 mRNA expression is an independent prognostic factor for clinical outcome. Our study provides useful information for future trials combining chemoradiation with immune checkpoint inhibitors and IDO1 inhibitors. © © Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.
Συγγραφείς:
Economopoulou, P.
Kladi-Skandali, A.
Strati, A.
Koytsodontis, G.
Kirodimos, E.
Giotakis, E.
Maragoudakis, P.
Gagari, E.
Maratou, E.
Dimitriadis, G.
Kotsantis, I.
Vagia, E.
Anastasiou, M.
Gkotzamanidou, M.
Kavourakis, G.
Lianidou, E.
Psyrri, A.
Εκδότης:
BMJ Publishing Group
Λέξεις-κλειδιά:
biological marker; cisplatin; epithelial cell adhesion molecule; indoleamine 2,3 dioxygenase; indoleamine 2,3 dioxygenase 1; messenger RNA; programmed death 1 ligand 1; unclassified drug; indoleamine 2,3 dioxygenase; indoleamine 2,3-dioxygenase 1, human; messenger RNA, advanced cancer; Article; cancer prognosis; cancer survival; chemoradiotherapy; circulating tumor cell; clinical outcome; cohort analysis; drug megadose; female; follow up; gene; gene expression; gene overexpression; head and neck squamous cell carcinoma; human; IDO1 gene; major clinical study; male; mRNA expression level; overall survival; progression free survival; prospective study; genetics; head and neck tumor; prognosis; tumor embolism, Head and Neck Neoplasms; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; RNA, Messenger; Squamous Cell Carcinoma of Head and Neck
DOI:
10.1136/esmoopen-2019-000646
